The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines

Tumor Biology

Volumn 29, Issue 4, 2008, Pages 245-254

  Rosso, Marisa ^a   Robles Frías, María Jose ^a   Coveñas, Rafael ^b   Salinas Martín, Manuel Vicente ^a   Muñoz, Miguel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Apoptosis; Gastrointestinal carcinoma; Human primary gastrointestinal adenocarcinoma; L 733,060; NK 1 receptor antagonists; NK 1 receptor isoforms; Substance P; Tachykinins

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; NEUROKININ 1 RECEPTOR; SUBSTANCE P;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MITOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STOMACH ADENOCARCINOMA; WESTERN BLOTTING;

EID: 51049102605     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000152942     Document Type: Article

References (34)

1. Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1-9.
2. Murray CJ, López AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.
3. Karpeh MS, Kelsen DP, Tepper JE: Cancer of the stomach; in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice on Oncology. Philadelphia, Lippincott, Williams and Wilkins, 2001, pp 1092-1126.
4. Burt RW: Colon cancer screening. Gastroenterology 2000;119:837-853.
5. Cohen AM, Minsky BD, Friedman MA: Rectal cancer; in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: principles and practice of oncology. Philadelphia, Lippincott, Williams and Wilkins, 1993, pp 978-1005.
6. Hökfelt T, Pernow B, Wahren J: Substance P: a pioneer amongst neuropeptides. J Intern Med 2001;249:27-40.
7. Harrison S, Geppetti P: Substance P. Int J Biochem Cell Biol 2001;33:555-576.
8. Luo W, Sharif TR, Sharif M: Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 1996;56:4983-4991.
9. Muñoz M, Pérez A, Coveñas R, Rosso M, Castro E: Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines. Arch Ital Biol 2004;142:105-112.
10. Muñoz M, Rosso M, Pérez A, Coveñas R, Rosso R, Zamarriego C, Piruat JI: The NK1 receptor is involved in the antitumoural action of L-733,060 and the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 2005;39:427-432.
11. Muñoz M, Rosso M, Pérez A, Coveñas R, Rosso R, Zamarriego C, Soult JA, Montero I: Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2005;46:2567-2570.
12. Muñoz M, Rosso M, Coveñas R: The NK-1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett Drug Des Discovery 2006;3:323-329.
13. Harrison T, Willians BJ, Swain CJ, Ball RG: Piperidine-ether based hNK1 antagonists 1: determination of the relative and absolute stereochemical requirements. Bioorg Med Chem Lett 1994;4:2545-2550.
14. Rupniak NM, Carlson E, Boyce S, Webb JK, Hill RG: Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain 1996;67:189-195.
15. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Halle JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlsson EJ, Hargreaves RJ, Rupniak NM: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640-1645.
16. 1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 2000;39:1413-1421.
17. Bang R, Sass G, Kiemer AK, Vollmar AM, Neuhuber WL, Tiegs G: Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J Pharmacol Exp Ther 2003;305:31-39.
18. 11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 1997;57:51-54.
19. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S: Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 2000;82:480-487.
20. Muñoz M, Pérez A, Rosso M, Zamarriego C, Rosso R: Antitumoural action of NK1 receptor antagonist L-733,060 on human melanoma cell lines. Melanoma Res 2004;14:183-188.
21. Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA: Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonists, L-732,138. Invest Ophthalmol Vis Sci 2007;48:2775-2781.
22. Caberlotto L, Hurd YL, Murdock P, Wahlin JP, Melotto S, Corsi M, Carletti R: Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur J Neurosci 2003;17:1736-1746.
23. McGillis JP, Organist ML, Payan DG: Immunoaffinity purification of membrane protein constituents of the IM-9 lymphoblast receptor for substance P. Anal Biochem 1987;164:502-513.
24. McGillis JP, Mitsuhashi M, Payan DG: Immunomodulation by tachykinin neuropeptides. Ann N.Y. Acad Sci 1990;594:85-94.
25. van Ginkel FW, Pascual DW: Recognition of neurokinin 1 receptor (NK1-R): an antibody to a peptide sequence from the third extracellular region binds to brain NK1-R. J Neuroimmunol 1996;67:49-58.
26. Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Buchler MW: Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 2003;83:731-742.
27. Hennig IM, Laissue JA, Horisberger U, Reubi JC: Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995;61:786-792.
28. Schulz S, Stumm R, Röcken C, Mawrin C, Schulz S: Immunolocalization of full-length NK 1 tachykinin receptors in human tumors. J Hystochem Cytochem 2006;54:1015-1020.
29. Muñoz M, Rosso M, Soult JA, Coveñas R: Antitumoural action of neurokinin-1 receptor antagonists on human brain cancer cell lines; in Yang AV (ed): Brain Cancer: Therapy and Surgical Intervention. New York, Nova Science Publishers, 2006, pp 45-75.
30. Singh D, Joshi DD, Hameed M, Qian J, Gascón P, Maloof PB, Mosenthal A, Rameshwar P: Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: Implications for bone marrow metastasis. Proc Natl Acad Sci USA 2000;97:388-393.
31. Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F: Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004;112:231-238.
32. 11]substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Bioph Res Com 1994;199:1313-1319.
33. Esteban F, Muñoz M, González-Moles MA, Rosso M: A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 2006;25:137-145.
34. Diemunsch P, Grelot L: Potential of substance P antagonists as antiemetics. Drugs 2000;60:533-546.